Varex Imaging Corp (VREX) · Oct 22, 2026 · Acquisition

Varex acquisition update adds lawsuits, keeps $18.90 deal intact

Merger unchanged — $18.90 cash consideration; October 28 vote unchanged

Varex’s acquisition update discloses two lawsuits and 13 demand letters, but leaves the $18.90 cash merger and October 28 vote unchanged.

Varex is a medical- and industrial-imaging components maker being acquired by Teledyne, with products including X-ray tubes, digital detectors and image-processing systems. This filing does not change that strategic endpoint; it supplements the merger proxy after shareholder litigation and demand letters.

The deal terms are unchanged. Varex says the supplemental disclosures do not affect the cash consideration or the timing of the special meeting. 〔0〕 The board continues to recommend approval, so the filing is not a renegotiation or a new bid signal.

The new wrinkle is execution risk, not economics. Two shareholder complaints and 13 demand letters allege proxy disclosure deficiencies and seek corrective disclosures, damages or an injunction. Varex calls the claims meritless, but the volume of challenges adds legal friction around a transaction that was already agreed and scheduled.

Regulatory timing is now clearer, but closing remains conditional. The HSR waiting period is set to expire at 11:59 p.m. Eastern time on November 19, 2026, while the U.K. national-security review runs through November 18. 〔1〕 〔2〕 The October 28 stockholder vote therefore comes before the key regulatory endpoints.

Merger referenceValueFiling location
Cash merger consideration$18.90/shareEvercore valuation analyses
Closing price on August 7, 2026$12.41/shareEvercore valuation analyses
Evercore DCF implied value$15.00–$21.50/shareDiscounted cash flow analysis
FY2027E EBITDA comparable-company value$11.25–$19.50/shareSelected Publicly Traded Companies Analysis
Selected-transactions implied value$13.25–$35.75/shareSelected Transactions Analysis
Analyst price-target range$12.00–$22.00/shareSelected Publicly Available Share Price Targets

Bottom line: This is mainly a procedural merger supplement: the price, vote timing and board recommendation stand, while shareholder lawsuits and outstanding regulatory reviews add some closing complexity without changing the transaction’s stated economics.

What to watch next

Stockholder vote, October 28, 2026

Original filing on SEC EDGAR

More Varex Imaging Corp news

Varex acquisition update adds lawsuits, keeps $18.90 deal intact | VREX Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.